Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YQ 23

Next Previous
Drug Profile

YQ 23

Alternative Names: YQ-23

Latest Information Update: 22 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New Beta Innovation
  • Class Anti-ischaemics; Antineoplastics; Haemoglobins
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic limb-threatening ischemia
  • No development reported Cancer; Liver cancer; Solid tumours

Most Recent Events

  • 08 Dec 2023 New Beta Innovation Limited terminates a phase I/II trial in Chronic limb threatening ischemia in Hong Kong (IV) due to business decision (NCT04792008)
  • 08 Dec 2023 New Beta Innovation Limited terminates a phase-I trial in Solid tumours (Second-line therapy or greater, Monotherapy, Combination, Late-stage disease) in Hong Kong (IV) due to business decision (NCT04513067)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Second-line therapy or greater) in Hong Kong (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top